August 29, 2014 10:27 PM ET

Pharmaceuticals

Company Overview of Epiphany Biosciences, Inc.

Company Overview

Epiphany Biosciences, Inc. develops and markets therapeutic products and diagnostic technologies that treat and prevent the spread of pathogenic viruses. The company develops therapeutics to prevent spread of varicella zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV). Epiphany Biosciences, Inc. is based in San Francisco, California.

One California Street

Suite 2800

San Francisco, CA 94111

United States

Phone:

415-765-7193

Fax:

415-765-7200

Key Executives for Epiphany Biosciences, Inc.

Vice President of Business & Corporate Development
Director of Drug Discovery and Development
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Asphelia Pharmaceuticals, Inc. United States
Diffusion Pharmaceuticals LLC United States
PepTx Inc. United States
Bend Research Inc. United States
Avion Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Epiphany Biosciences, Inc., please visit www.epiphanybio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.